Columbia/HCA puts ValueRx up for sale three weeks after completing purchase of PBM.
COLUMBIA/HCA PUTS VALUERx BACK UP FOR SALE as part of divestment plans adopted by new management following the indictment of three company officials for alleged Medicare fraud. Just three weeks after completing the $1.1 bil. acquisition of Value Health, Columbia/HCA has decided to divest three of the company's four lines of business, including the ValueRx pharmacy benefit management company.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth